This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Memantine induces reversible neurologic impairment in patients with MS
The authors conducted a one year, randomized, double blind, crossover study comparing memantine against placebo in 60 patients with MS and cognitive impairment. They found that memantine at a dose of 30 mg/day may induce transient worsening of neurologic symptoms of MS.
See p. 1630; Editorial, p. 1626
Age and founder effect of SOD1 A4V mutation causing ALS
This paper emphasizes the importance of finding ALS patients of nonwhite lineages especially of the American Indian. It proposes the existence …
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.